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Abstract 
Nanomedicines in the class of non-biological complex drugs (NBCDs) are becoming 
increasingly available. Up to 23 nanomedicines have been approved, and approximately 50 
are in clinical development. Meanwhile, the first nanosimilars have entered the market 
through the generic approval pathway, but clinical differences have been observed. Many 
healthcare professionals may be unaware of this issue and must be informed of these 
clinically relevant variances. This article provides a tool for rational decision making for the 
inclusion of nanomedicines into the hospital formulary, including defined criteria for 
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evaluation of substitutability or interchangeability. The tool was generated by conducting a 
round table with an international panel of experts and follows the same thought process as 
developed and published earlier for the selection of biologicals/biosimilars. In addition to the 
existing criteria for biosimilars, a set of seven criteria were identified that specifically apply 
to nanosimilars. These include (1) particle size and size distribution, (2) particle surface 
characteristics, (3) fraction of uncaptured bioactive moiety, (4) stability on storage, (5) 
bioactive moiety uptake and (6) distribution, and (7) stability for ready-to-use preparation (7). 
Pharmacists should utilize their pharmaceutical expertise to use the appropriate criteria to 
evaluate the comparability of the drug to decide on interchangeability or substitutability. 
 
Keywords: nanomedicines; nanosimilars; hospital formulary; interchange; substitution 
 
Introduction 
Recently, a discussion emerged on the therapeutic equivalence of non-biological complex 
drug (NBCD) products and their follow-on versions, also referred to as NBCD similar (see 
Box 1 for glossary of terms). One distinct class of NBCDs are nanomedicines, which can be 
defined as medicinal products developed and manufactured using nanomaterials and 
nanotechnology and consisting of multiple structures. This is a rapidly expanding field in 
medicine. A total of 23 parenteral non-biological nanomedicines have been approved, and 52 
more are under clinical investigation.
1
 Examples of available nanomedicines are given in 
Table 1. With the first patents expiring, large market opportunities for nanosimilars are 
opening up. Examples of first-generation nanomedicines that came off patent are iron–
carbohydrate (iron–sugar) drugs, a number of liposome products, and glatiramoids.2,3 Follow-
on versions appeared on the market with the introduction of iron–sucrose similars (ISS), 
approved via the approval pathway of small molecule generic products. Authorization of 
these generic products is based on showing pharmaceutical equivalence and bioequivalence 
to the listed reference product, ultimately leading to therapeutic equivalence and 
interchangeability or substitutability. This authorization process proved successful for fully 
characterizable small molecule products. However, owing to the complexity of 
nanomedicines, showing equivalence is more challenging for follow-on products of 
nanomedicines (further referred to as nanosimilars).
4
 This has been clinically shown for iron 
sucrose, but potentially accounts for all nanosimilars. After market introduction of ISS, which 
were approved on the basis of physicochemical comparability to the iron–sucrose originator 
(Venofer®) but without considering the nanocolloidal character of the products, efficacy and 
safety issues were observed in the clinic.
5–9
 Alarmed by these findings, discussion on the 
regulatory approval pathway of follow-on nanomedicines was started by the European 
Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
2,10–12
 
The rationale behind designing nanomedicines is to optimize and enlarge the 
therapeutic use of drugs, for example by improving drug delivery (e.g., by controlled and/or 
site-specific drug release or improved drug transport across biological barriers). 
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Nanomedicines are by definition different from biologicals and therefore not assessed via the 
biosimilar pathway, although nanomedicines share a comparable or even increased level of 
complexity. However, the regulatory experience with biosimilars can be of assistance for 
shaping the landscape of nanosimilars, since some basic evaluation criteria have been defined 
already in the biosimilar approval paradigm. These requirements include pharmacological 
aspects (i.e., clinical efficacy and safety)
13
 and pharmaceutical aspects (i.e., evaluation of 
physicochemical properties, biological activity, immunochemical properties, purity, and 
quantity).
14
 
Notably, the interchangeability or substitutability of nanosimilars and their listed 
reference product(s) cannot be taken for granted. Therefore, it is of great importance that 
pharmacists who have to evaluate such nanosimilars become familiar with the concept and 
complexity of nanomedicines before including nanosimilars in the hospital formulary and 
elaborating the necessary guidance for use.  However, a survey among hospital pharmacists 
in France and Spain showed alarmingly low awareness about the clinical differences between 
various intravenous (i.v.) iron products.
15
 Consequently, such drug selection decisions and 
subsequent drug interchange/substitution practices are neither consistent nor based on 
scientifically and clinically sound criteria among various hospitals. Despite studies published 
in peer-reviewed papers showing clinical differences between the originator and its follow-on 
products, a high proportion of nanosimilars are being dispensed. Because these clinical 
differences among nanomedicines and approved follow-on products are observed, the 
pharmacists should bring in their expertise about structure–activity relationships to ensure 
safe and efficacious use of nanomedicines for the sake of patients. In the case of biosimilars, 
the EMA has stated that market authorization as a biosimilar does not automatically imply 
interchangeability with the originator.
16
 Consequently, evaluation criteria have been 
published for healthcare professionals to judge the substitutability and interchangeability of 
biosimilars to make a rational decision for formulary inclusion. At present, there are no such 
tools available for the evaluation of nanosimilars for hospital formulary inclusion.
17,18
  
Here, we intend to provide a tool for rational decision making for the inclusion of 
nanomedicines into the hospital formulary, including defined criteria for evaluation of 
substitutability or interchangeability. We aim to provide a framework that defines a 
reasonable totality of evidence needed to decide on therapeutic equivalence or therapeutic 
interchange of nanosimilars. On the basis of this proposal, national policies may be adapted 
and implemented. 
 
Methods 
A consensus round table session with leading expert hospital pharmacists from Belgium, 
France, Germany, Spain, Switzerland, and the United States was organized to identify and 
discuss the criteria that are specifically important for the evaluation of nanosimilars. 
Previously defined formulary selection criteria for biosimilars were summarized and provided 
as a literature-based algorithm to the chair (H.P. Lipp, a pharmacist), who used it as a starting 
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point for discussion.
17,18
 On top of this, additional nanosimilar-specific criteria were 
identified during the discussion. Concluding statements on discussion points or specific 
criteria were considered as consensus upon unambiguous agreement on the respective topic 
among the participants. 
 
Results 
In contrast to small molecules, large, non-homomolecular nanomedicines require additional 
attention regarding their physicochemical characteristics, namely the physical stability of 
particles during shelf life and in ready-to-use drug preparations. Another important aspect is 
the particle interaction with the innate immune system, which influences the pharmacokinetic 
(PK) and pharmacodynamic (PD) profiles of the drug. 
In addition to the existing formulary inclusion criteria for biosimilars,
16
 seven 
nanosimilar-specific criteria have been identified: particle size and size distribution, particle 
surface characteristics, fraction of uncaptured bioactive moiety, stability on storage and 
ready-to-use stability, and fate in the body, more specifically uptake and distribution (Fig. 1).  
In Table 2, these criteria are turned into questions that should be used as a structured 
tool for the evaluation of nanosimilars. As we aim to give the complete picture of selection 
criteria for such nanosimilars, non-drug-specific criteria like product labeling aspects, supply, 
and manufacturer evaluation are also given in Table 2.  
In the following sections, the criteria are discussed in detail using relevant scientific data 
from various examples of nanomedicines. As ISS were the first nanomedicine follow-on 
products introduced, there are unique clinical data published showing the challenges faced 
with generic substitution of nanomedicines. Therefore, iron–sucrose can be seen as a 
representative of the nanomedicine drug class and the challenges encountered when similars 
are marketed for which equivalence has not appropriately assessed, leading to therapeutic 
nonequivalence.  
 
Pharmaceutical quality  
Particle size and size distribution. Particle size influences uptake, biodistribution, and 
degradation of the nanomedicine and therefore the drug’s pharmacokinetic profile.19–21 As 
shown in Figure 2, differences in the size of polystyrene particles result in an altered spleen 
uptake after i.v. administration in rats.
19
 Larger particles (200 nm and above) are more 
efficiently taken up from the blood by Kupffer cells compared with their smaller 
counterparts.
22,23
 Another important aspect to evaluate is the size distribution, since 
nanomedicines are often heterogeneous colloidal dispersions covering a range of particle 
sizes. Even though nanosimilars may have the same average size, their particle size 
distribution can still differ, resulting in a changed biodistribution and therapeutic profile. 
Therefore, not only the average particle size but also the size distribution must be compared.  
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Particle surface characterization. The particle’s morphology and surface can influence 
clinical efficacy and safety. First, biodistribution is affected by the character of the 
nanoparticulate structure, as shown in studies in mice.
21,24
 This finding is supported by 
pharmacovigilance results from different i.v. iron products. The available i.v. iron products 
are all colloidal dispersions, but the carbohydrates stabilizing the iron cores differ physically 
(e.g., linear/branched; mono-/oligo-/polysaccharides). In the United States, 
pharmacovigilance studies revealed large differences in reported deaths and adverse 
events.
25,26
 Additionally, the charge of the nanoparticle should be assessed, since differences 
in charge may alter PK and the clinical outcome. Different values for the zeta potential of 
gold nanoparticles showed a significantly different distribution in organs, tissues, and body 
fluids.
23
 Interaction of nanoparticles with body fluids after injection may lead to different 
opsonization patterns, which in turn can influence interactions with cell membranes and 
toxicity. Their exact surface structure in the biological environment is still not fully 
understood today, and hence yet-unknown physicochemical parameters can further influence 
drug disposition.  
Uncaptured bioactive moiety fraction. The PK/PD profile of a nanomedicine is determined 
by the entire structure of the nanoparticle. The bioactive moiety of nanomedicines is 
embedded (captured) in non-homomolecular nanostructures. Therefore, the properties of such 
medicinal products are defined by the entire formulated product, which has to be 
characterized as a whole. Ideally, the nanomedicine consists of a homogeneous colloidal 
dispersion of intact nanoparticles. However, in reality, a distinction should be made between 
the captured bioactive moiety and an uncaptured, non-nanoparticular bioactive moiety 
(sometimes also expressed as free molecule or labile moiety content). This relationship can 
vary depending on the type of nanoparticles and manufacturing conditions. The nanoparticle 
can, depending on its environment, stability, and/or reactivity, decompose or aggregate,
27
 as 
shown in Figure 3. High levels of uncaptured bioactive moiety present in solution upon 
administration affect the pharmacokinetics of the nanomedicine, with implications for its 
efficacy and safety. This was observed in the case of i.v. iron products. For unstable i.v. iron 
preparations, a higher amount of labile iron (uncaptured bioactive moiety) is directly released 
into the bloodstream, where it binds to transferrin. When labile iron is released in serum 
above a certain level, transferrin becomes saturated, and highly reactive non-transferrin-
bound iron (NTBI) is formed, which is hypothesized to cause oxidative stress and eventually 
inflammation and may have acute and long-term consequences.
28–30
 Elevated transferrin 
saturation (TSAT) and increased inflammation markers were observed in hemodialysis 
patients after administration of ISS, compared with IS.
5,6
 In the case of liposomal doxorubicin 
preparations, administration of Lipodox® (a nanosimilar of Doxil®/Caelyx®) in a human 
ovarian cancer mouse model resulted in only approximately half of the intratumoral 
doxorubicin concentrations compared with equal doses of the originator nanomedicine.
31
 The 
lower drug availability is in line with reduced efficacy in the mouse model, as well as lower 
or no efficacy of Lipodox in ovarian cancer treatment compared with Doxil, as was observed 
during a national shortage of Doxil in the United States.
32,33
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Stability on storage. Acknowledging the critical importance of the preservation of 
nanoparticulate characteristics of nanomedicines over time, in addition to the chemical 
stability, all aspects that were discussed above regarding the physical state of the 
nanoparticles need to be assessed when establishing their shelf life. Special attention should 
be paid to ensure stability of the uncaptured/captured ratio of the bioactive moiety, as well as 
the degree of aggregation/decomposition (Fig. 3), by measuring particle size and size 
distribution. 
 
Pharmacokinetics  
Uptake and distribution. Nanomedicines from different manufacturing processes may have 
different uptake and distribution characteristics. The nanomedicine is administered as 
nanoparticles in the bloodstream, and its bioactivity depends on the degradation of the 
particle and release of the bioactive moiety, which is often handled by the innate immune 
system. Particles are actively taken up by the cells of the mononuclear phagocyte system 
(MPS) in the liver, spleen, and bone marrow. In these cells (macrophages), degradation takes 
place, and the bioactive moiety is released.
34
 Subtle changes in particle composition (e.g., 
size or charge) can affect the biodistribution of the nanosimilar.
19–23,34,35
 In the case of 
PEGylated nanoparticles, a hydrodynamic radius of less than 150 nm was shown to produce 
an increased uptake of particles in the bone marrow of rabbits, whereas particles with a 
diameter of 250 nm were mostly sequestered in the spleen and liver, with only a small 
fraction of uptake by the bone marrow.
36
  
Differences in uptake and tissue distribution profiles between originator nanomedicines 
and their nanosimilars were observed among liposomal doxorubicin preparations as well as 
various ISS.
31
 The correlation between biodistribution and physicochemical properties is not 
fully understood, and plasma PK studies alone are not sufficiently informative about the 
drug’s fate in the body. Despite this, in contrast to EMA, the FDA does not require 
biodistribution data for approval of follow-on intravenous iron nanomedicines.
37,38
  
 
Ready-to-use preparation and administration 
Stability for ready-to-use administration. The efficacy and safety profiles of 
nanomedicines depend on the protocol for making the product ready for use by the 
pharmacist or nurse. The physicochemical properties, in combination with the environment 
(dilution, type of infusion fluid, pH, nature of primary packaging), can affect the integrity of 
the medicinal product, destabilize the nanoparticle leading to particle aggregation or 
undesired drug release, or trigger adsorption phenomena. It was shown in a retrospective 
clinical survey that inappropriate dilution can affect the safety profile of nanomedicines.
7
 In a 
gynecology ward, a significant increase of adverse events was observed upon switching 
patients from IS to ISS. With the intention to mitigate this effect and to improve tolerance, 
the amount of saline in the infusion was increased according to the routine for small 
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molecular solutions. The nanoparticles were destabilized, and the number of adverse events 
further increased (Fig. 4).
7
 Therefore, it is of utmost importance to ensure that data is 
available showing stability of the nanomedicine when diluted for infusion.
39
 
 
Discussion 
Nanomedicines, as a distinct subgroup of NBCDs, should be given special attention when 
evaluated in a drug formulary committee. For the first follow-on products approved by the 
generic pathway, differences in the clinical efficacy and safety were reported in the scientific 
literature after their approval. This created doubts about their therapeutic equivalence and 
hence their interchangeability/substitutability. Owing to the fact that these nanomedicines 
consist of non-homomolecular structures and are not fully characterizable by 
physicochemical techniques and because the biological interaction of the nanoparticles with 
the body is presently not fully understood, additional aspects need to be considered when 
evaluating the comparability of a nanosimilar with the originator medicinal product. Two 
specific areas were identified where the nanoparticulate characteristics of these drugs can 
lead to clinically meaningful differences and require specific attention beyond the criteria 
used for small molecules and biologics: (1) physical stability of the colloidal dispersion 
during shelf life and the ready-to-use preparation of the drug (e.g., dilution) and (2) 
pharmacokinetic consequences of the direct interaction of the nanoparticles with the innate 
immune system as part of their intended, targeted uptake mechanism.  
The pharmacokinetics are much more complex compared with those of small 
molecules. The uptake involves active processes like phagocytosis, and the PK depend 
strongly on the physicochemical characteristics of the nanostructures. Therefore, 
nanosimilars have to be evaluated differently from generics to form conclusion on 
comparability. In order to make a rational decision about interchangeability or 
substitutability, pharmacists should evaluate clinical data on therapeutic equivalence rather 
than bioequivalence only. 
First, equivalence should be shown regarding pharmaceutical quality criteria, 
including particle size, size distribution, particle character, uncaptured bioactive moiety and 
the release from the captured form, and particle stability. 
Second, since a direct correlation has not been found between the physicochemical 
properties of a nanomedicine and its clinical efficacy and safety, nonclinical and clinical 
pharmacokinetics, specifically uptake and biodistribution, must be evaluated. In order to 
determine the interchangeability and substitutability of nanosimilars, therapeutic equivalence 
of efficacy and safety has to be demonstrated in a relevant clinical setting. Relevant clinical 
differences of a nanosimilar and the reference product cannot be excluded without the 
necessary scientific data, including comparative clinical outcome studies. Pharmacists have to 
bring their specific pharmaceutical expertise to the evaluation of this type of drugs, using a 
structured tool such as the one suggested in Table 2, enabling them to make a science-based 
selection of nanosimilars for the drug formulary. At present, the amount of comparative data 
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in the public space is limited and mainly restricted to iron sucrose and liposomal doxorubicin 
preparations. A nanosimilar is not by definition therapeutically worse than its reference 
product, but publically available clinical data should confirm this before a statement can be 
made about the therapeutic equivalence. Comparative data should be available if a 
nanosimilar is approved in an appropriate manner according to the proposed 
requirements.
10,11 
 
 
Conclusions 
Follow-on products of nanomedicines have in the past been approved by the generic 
pathway; however, differences in clinical efficacy and safety were reported in the scientific 
literature after their approval. Healthcare professionals must be aware that nanosimilars may 
exert clinically relevant differences compared with the originator products. This article 
provides a structured tool (questionnaire) that can help pharmacists evaluate a nanosimilar 
medicinal product and decide upon interchangeability or substitutability based on their 
unique pharmaceutical expertise. 
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Figure legends 
Figure 1. Formulary selection criteria for nanosimilars. The nano-specific criteria are 
highlighted in red. CSTDs, closed-system transfer devices. Adapted with permission from the 
American Society of Health-System Pharmacists.
17,42  
 
Figure 2. Effect of particle size on the spleen uptake of poloxamer-407–coated polystyrene 
particles after i.v. administration to rats. Reproduced from Ref. 20
. 
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Figure 3. Schematic overview of different physical forms of nanoparticles possibly present in 
a heterogeneous colloidal nanoparticle solution. 
 
Figure 4. Effect of IS dilution on adverse side effects. IS original was diluted in 100 mL 
saline. Reproduced from Ref. 7. 
 
 
Box 1. Glossary of terms 
Bioequivalence (BE) is considered to bedemonstrated if the 90% confidence intervals of the 
ratios for log AUC0–t and Cmax between the two preparations lie in the range 80.00–125.00% 
correlating to a 90% BE confidence interval.
40
 
Dynamic light scattering is a technique to determine the size distribution profile of small 
particles in suspension. A laser beam illuminates the suspension, and the fluctuations of the 
scattered light are detected by a fast photon detector. 
Nanomedicine is a medicinal product developed and manufactured using nanomaterials and 
nanotechnology and often comprising multiple structures, biological or nonbiological.  
Nanosimilar is a follow-on product of a reference nanomedicine.
4
 
NBCD. A medicinal product, not being a biological medicine, where the active substance is 
not a homomolecular structure, but consists of different (closely) related and often 
nanoparticulate structures that cannot be isolated and fully quantitated, characterized, and/or 
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described by physicochemical analytical means. It is also unknown which structural elements 
might affect the therapeutic performance. The composition, quality, and in vivo performance 
of NBCDs are highly dependent on the manufacturing processes of both the active ingredient 
and the formulation. Examples of NBCDs include liposomes, iron–carbohydrate (iron–sugar) 
drugs, and glatiramoids.
40
 
Interchangeability at the individual level means that, in an individual patient, two medicinal 
products that are believed to be therapeutically equivalent can be alternated or switched with 
the authorization of the initial prescriber. Interchangeability at the individual level is a 
condition for substitution.
40,41
 
Interchangeability at the population level means that two medicinal products that are 
believed to be therapeutically equivalent can be used for treatment for the same condition in 
the same population.
40
 
Pharmaceutical equivalence implies the same amount of the same active substance(s), in the 
same dosage form, for the same route of administration and meeting the same or comparable 
standards. 
Substitutability means a dispensing policy to allow replacement at the individual level of a 
medicinal product for a similar/bioequivalent medicinal product without the prior 
authorization of the initial prescriber.
40,41
 
Switchability means that the product can be changed (e.g., from reference product to 
biosimilar or vice versa) in a patient during the course of treatment.
40
 
Therapeutic equivalence of two different products enables the products to be interchanged. 
Two medicinal products with systemic effects are therapeutically equivalent if they are 
pharmaceutically equivalent and if their bioavailabilities after administration at the same 
molar dose are similar to such a degree that their effects, with respect to both efficacy and 
safety, will be essentially the same (bioequivalent).
40
 
Zeta potential is the electric potential of the surface of a (solid) particle immersed in a liquid 
relative to a point in the bulk fluid away from the interface. 
 
Table 1: Examples of parenteral nanotherapeutic products on the market, including similars if available. 
Nanotechnology  Active substance Indication Brand name 
originator  
Nanocrystals Olanzapine Schizophrenia Zypadhera® 
Paliperidone Schizophrenia Xeplion®(EU)/
Invega®(US) 
Polymeric drugs Pegaptanib Wet macular 
degeneration 
Macugen® 
Glatiramer 
acetate  
Multiple 
sclerosis 
Copaxone® 
(similars 
available) 
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Liposomes Amphotericin B Fungal 
infections 
AmBisome® 
Cytarabine Meningeal 
neoplasms 
DepoCyt® 
Bupivacaine Anesthetic  Exparel® 
Daunorubicin  Cancer 
advanced HIV-
associated 
Kaposi’s 
sarcoma 
DaunoXome® 
Doxorubicin 
hydrochloride 
(PEGylated) 
Breast 
neoplasms; 
multiple 
myeloma; 
ovarian 
neoplasms; 
Kaposi’s 
sarcoma 
Caelyx®(EU)/ 
Doxil®(U.S.) 
  ipo o    –
similar in 
U.S.)  
Doxorubicin 
hydrochloride 
Breast 
neoplasms  
Myocet® 
Morphine Pain relief DepoDur® 
Mifamurtide Osteosarcoma Mepact® 
Verteporfin Macular 
degeneration, 
myopia, 
degenerative 
Visudyne®  
Vincristine  Philadelphia 
chromosome–
negative acute 
lymphoblastic 
leukemia 
Marqibo®  
Nanoparticles Aprepitant  Nausea and 
vomiting 
Emend® 
Paclitaxel Metastatic 
breast cancer 
Abraxane® 
Ferric 
carboxymaltose  
Iron deficiency  Ferinject®(EU
)/Injectafer® 
(U.S.) 
Ferumoxytol Iron deficiency Rienso®(EU)/
FeraHeme®(U
.S.) 
High-molecular-
weight iron–
dextran 
Iron deficiency Dexferrum® 
Low-molecular-
weight iron–
dextran 
Iron deficiency Cosmofer® 
Iron gluconate Iron deficiency Ferrlecit® 
Iron isomaltoside 
1000 
Iron deficiency Monofer® 
Iron sucrose Iron deficiency Venofer® 
(similars 
available) 
 
Table 2: Questions to ask for evaluating NBCDs and nanosimilars,  
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Evaluation criteria of nanosimilars for 
formulary inclusion 
Pharmaceutical quality  
Chemical composition Chemical components in the 
formulation of the 
nanosimilar  
Identity  Are the chemical structures 
of the active ingredients 
similar? 
- Pharmacological 
active moiety  
- Nanoparticulate 
structure 
Quantity  Are there differences in 
quantity of the 
pharmacological moiety in 
the formulations of the 
nanosimilar compared with 
the reference product? 
Pharmacopoeial 
specifications 
Are there any differences 
between the properties of 
the nanosimilar under 
consideration and the 
pharmacopoeial 
specifications of the 
reference product? 
Particle size and size 
distribution 
Does the average size of the 
nanosimilar differ from the 
reference product? 
Is there a similar size 
distribution between the 
nanosimilar under 
consideration and the 
reference product?  
Particle surface 
characteristics  
Do particle 
morphology/surface and 
charge/zeta potential differ 
from the reference product? 
Uncaptured pharmacological 
active moiety 
Is the fraction of free active 
moiety released at the time 
of administration similar 
compared to the reference 
product, shown in in vitro 
and in vivo studies? 
(ratio uncaptured/captured 
active moiety) 
Storage stability Are there differences in shelf 
life between the nanosimilar 
under consideration and the 
reference product? 
Is the ratio of 
captured/uncaptured active 
moiety included in the 
criteria for the determination 
of the shelf life of the 
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nanomedicine? 
Is the degree of aggregation 
of the nanoparticles included 
for the determination of the 
shelf life of the 
nanomedicine? 
Efficacy/safety 
Pharmacokinetics  Are there nonclinical and/or 
clinical studies available 
showing the (comparative) 
uptake of the active 
pharmaceutical ingredient?  
- Are there major 
differences between 
the nanosimilar 
under consideration 
and the reference 
product regarding 
the interaction with 
the innate immune 
system or plasma 
clearance? 
Are there differences in 
biodistribution profiles 
between the nanosimilar 
under consideration and the 
reference product? 
- What is the effect of 
these differences on 
the efficacy and 
safety and use 
compared to the 
reference product? 
Clinical data Is there a sufficient amount 
of clinical data available for 
the indications being 
considered for formulary 
inclusion? 
If appropriate, have head-to-
head evaluations been done 
in patients? 
Have postapproval studies 
been evaluated? 
Are relevant clinical data 
from peer-reviewed studies 
available? 
Indications Is the reference product 
currently used for multiple 
indications?   
- If yes, is the 
nanosimilar under 
consideration being 
evaluated for all 
those same 
indications, 
including EMA-/FDA-
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approved 
indications and 
those considered 
standard of care? 
Immunogenicity Are there any differences in 
the immunogenic profiles 
between the nanosimilar 
under consideration and the 
reference product with 
respect to the incidence of 
hypersensitivity reactions 
(e.g., hypersensitivity, 
anaphylactic reaction, cross 
reaction)?   
Therapeutic 
interchange/substitution 
Does scientific clinical 
evidence support the 
nanosimilar under 
consideration to be 
automatically substituted for 
the reference product (and 
vice versa)?  
Will patients who are taking 
the reference product at 
home be required to convert 
to the nanosimilar under 
consideration?  
- If yes, how will the 
drug transition be 
managed? Will 
policies need to be 
developed to 
specifically manage 
therapeutic care 
transitions? 
Are there any differences 
between the nanosimilar 
under consideration and the 
reference product regarding 
tolerance and compatibility 
(e.g., injection pain and 
interference with laboratory 
assays)?  
Manufacturer considerations 
Supply-chain reliability  Are there any differences in 
the hospital use and/or retail 
availability between the 
nanosimilar under 
consideration and the 
reference product that may 
affect the overall availability 
of the product? 
Does the manufacturer have 
a process to ensure a reliable 
and continuous supply of the 
product? 
Does the manufacturer 
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maintain adequate levels of 
product in stock locally and 
available on demand?  
Does the manufacturer have 
more than one 
manufacturing location, if 
necessary, to meet demand?  
- What is the time 
effect on product 
availability? 
- What is the effect 
on the pro uct’s 
costs? 
History of drug shortages  Has the manufacturer 
experienced shortages of this 
or other products in the 
past? 
Has the product ever been 
recalled owing to quality 
concerns? 
Have other products of the 
manufacturer ever been 
recalled as a result of quality 
concerns? 
Supply-chain security  Does the manufacturer apply 
and document adequate 
security technologies for 
product authentication, 
warehouse/cargo security, 
and market surveillance to 
detect potential product 
diversion or counterfeits?  
 Does the manufacturer 
document and maintain 
controlled temperature 
during stock and 
transportation of the product 
(GDP)? 
 Does the manufacturer take 
the necessary steps to 
prevent damage or potential 
(exterior) contamination of 
vials? 
Anti-counterfeit measures Does the manufacturer 
possess a program to protect 
against counterfeiting? 
Patient assistance programs Does the manufacturer 
provide patient assistance 
programs that are necessary 
or advantageous for the 
patient’s care? 
Reimbursement support  Are reimbursement support 
and other programs (e.g., 
product replacement, co-
payment assistance, and 
insurance denial support) 
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available for 
uninsured/underinsured 
patients receiving the 
nanosimilar under 
consideration?   
- If not, will the 
overall cost of 
adding the 
nanosimilar under 
consideration to 
formulary be 
affected? 
Manufacturer services, 
expertise 
Is the company a relevant 
and recognized player for 
healthcare products?  
Product considerations  
Product packaging  Are the containers, 
packaging, and labeling well 
designed and easy to read 
and to distinguish (in order to 
prevent medication errors)? 
Are there any differences in 
packaging between the 
nanosimilar under 
consideration and the 
reference product? 
Are there any differences in 
warning labels regarding use 
and handling between the 
nanosimilar under 
consideration and the 
reference product? 
Barcoding Is the labeling of the 
nanosimilar under 
consideration compatible 
with the facility’s current 
technology? 
Compatibility with CSTDs, 
robotics  
Are there any differences in 
compatibility with CSTDs or 
robotics between the 
nanosimilar under 
consideration and the 
reference product? 
Ready-to-use preparation 
and administration 
Is there any data available on 
stability upon dilution or 
interactions with container 
materials (e.g., infusion bags) 
for the nanosimilar under 
consideration compared with 
the reference product? 
- Are there relevant 
differences affecting 
the use compared 
with the reference 
product? 
Are there any differences in 
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the delivery system or device 
between the nanosimilar 
under consideration and the 
reference product (e.g., 
autoinjector)? 
- Does the labeling for 
the nanosimilar 
under consideration 
include information 
on administration? 
- What is the plan for 
educating patients 
receiving a 
nanosimilar with an 
administration 
system/device 
different from the 
reference product? 
Does the nanosimilar under 
consideration have fewer 
approved routes of 
administration than the 
reference product? 
If provided in vials, are there 
any differences in the 
amount of excess product 
between the nanosimilar 
under consideration and 
reference product (filling 
volume)? 
Are there any differences in 
need of pharmacy technician 
time and techniques for 
compounding between the 
nanosimilar under 
consideration and reference 
product? 
Are there any differences in 
administration time or 
patient experience that may 
affect patient and nurse 
preference between the 
nanosimilar under 
consideration and reference 
product? 
Storage requirements  Are there differences in shelf 
life or storage requirements 
(e.g., light and temperature 
protection) between the 
nanosimilar under 
consideration and reference 
product?  
Do any differences in storage 
conditions offer an 
advantage or disadvantage in 
terms of patient care? 
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Will both the nanosimilar 
under consideration and the 
reference product be stored 
based on differing 
indications? 
- If so, how will the 
nanosimilar under 
consideration and 
reference product 
be stored to 
eliminate the 
potential for a 
dispensing error? 
Are there any differences in 
product packaging (e.g., size 
or shape) between the 
nanosimilar under 
consideration and the 
reference product that could 
affect compatibility with a 
robotic compounder? 
Hospital and patient factors 
Economic considerations Will all governmental and 
commercial payer policies 
apply equally to both the 
reference product and the 
nanosimilar under 
consideration? 
Are there any differences 
between the nanosimilar 
under consideration and 
reference product with 
respect to ease of access to 
the product? 
Are there financial and/or 
legal risks of using the 
nanosimilar under 
consideration for an 
unapproved indication for 
which the reference product 
has approval? 
Does the difference in cost 
for the nanosimilar under 
consideration versus the 
reference product support a 
full formulary conversion, 
including necessary changes 
in internal guidance and 
usage policies? 
Transition of care Will the patients who are 
taking the reference product 
at home be required to 
convert to the nanosimilar 
under consideration? 
- If yes, how will care 
transitions be 
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managed? 
- Will policies be 
developed to specify 
manage care 
transitions? 
IT and medication system 
changes 
Does the hospital have a 
robust information 
technology infrastructure to 
support: 
- Distinguishing the 
nanosimilar under 
consideration from 
the reference 
product during 
order entry? 
- Tracking which 
product was 
administered? 
Educational requirements  Does the manufacturer 
provide patient education 
materials? Do materials 
appropriately distinguish 
nanosimilars and generics? 
Is it necessary to develop 
materials for educating 
patients on the 
interchangeability of 
nanosimilar? 
Pharmacovigilance 
requirements 
What specific measures are 
needed to fulfill the authority 
requirements for PV? 
Are there ongoing clinical 
trials to foster necessary 
indications or precaution 
measures? 
 
NOTE: Derived and modified from Ref 15. The specific criteria for nanosimilars are added and colored in red. CSTDs, closed 
system transfer devices 
 
